UROS BUMBASIREVIC^1,2,*, MARKO ZIVKOVIC¹, MILOS PETROVIC¹, VESNA CORIC^2,3, NIKOLA LISICIC¹, NEBOJSA BOJANIC^1,2

Oncology Research, Vol.30, No.3, pp. 117-128, 2022, DOI:10.32604/or.2022.027511 - 12 January 2023

Abstract Seminomas are most commonly diagnosed in clinical stage I (CSI). After orchiectomy, approximately 15% of patients in this stage have subclinical metastases. Adjuvant radiotherapy (ART) delivered to the retroperitoneum and ipsilateral pelvic lymph nodes has been the mainstay of treatment for many years. Although highly efficient, with long-term cancer-specific survival (CSS) rates approaching almost 100%, ART is associated with considerable long-term consequences, particularly cardiovascular toxicity and increased risk of secondary malignancies (SMN). Therefore, active surveillance (AS) and adjuvant chemotherapy (ACT) were developed as alternative treatment options. While AS prevents patient overtreatment, it is associated with… More >

Alexander H. Wu¹, Supreet Kaur², Sharon Peng², Ashima Kapoor¹, Michael Maroules²

Canadian Journal of Urology, Vol.26, No.3, pp. 9799-9801, 2019

Abstract Most germ cell tumors are located in the gonads however there are instances where these tumors are located elsewhere in which are termed extragonadal germ cell tumors. When primary lesion of the testicular tumor has regressed, the term “burned-out testicular tumor” has been proposed. We herein report the first case of burned-out seminoma of the testis presenting as a cervical spinal mass causing cord compression with bone metastasis. More >

Christopher M. Russell^*, Pranav Sharma^*, Gautum Agarwal, John S. Fisher, George J. Richard, Philippe E. Spiess, Julio M. Pow-Sang, Michael A. Poch, Wade J. Sexton

Canadian Journal of Urology, Vol.23, No.1, pp. 8127-8134, 2016

Abstract Introduction: To evaluate whether varying degrees of seminomatous elements in the primary orchiectomy specimen would be predictive of patient morbidity during post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) since the desmoplastic reaction with seminoma is associated with increased intraoperative complexity.
Materials and methods: We retrospectively identified 127 patients who underwent PC-RPLND for residual retroperitoneal masses. Clinicodemographic, intraoperative, and 30 day postoperative outcomes were compared for patients with pure seminoma (SEM), mixed germ cell tumors (GCT) containing seminoma elements (NS+SEM), and tumors with no seminoma elements (NS). Multivariate logistic regression was used to determine independent predictors of intraoperative and… More >

Steven Kheyfets, Waleed Eisa, Heinric Williams

Canadian Journal of Urology, Vol.22, No.3, pp. 7827-7829, 2015

Abstract We present a case report of testicular seminoma with intraluminal metastasis to the ureter causing obstruction and hydronephrosis. To our knowledge, this is the fourth case to be reported in the world literature of metastatic tumor to the ureter from a primary testicular seminoma. More >

Pranav Sharma^1,*, Einar F. Sverrisson^2,*, Kamran Zargar-Shoshtari¹, Mayer N. Fishman¹, Wade J. Sexton¹, Shohreh I. Dickinson³, Philippe E. Spiess¹, Michael A. Poch¹, Scott M. Gilbert¹, Julio M. Pow-Sang¹

Canadian Journal of Urology, Vol.22, No.4, pp. 7882-7889, 2015

Abstract Introduction: We present our experience with minimally-invasive retroperitoneal lymph node dissection (MI-RPLND) in the post-chemotherapy (PC) setting for residual masses in patients with nonseminoma.
Materials and methods: Nineteen men who underwent PC MI-RPLND (14 – laparoscopic, 5 – robotic) for low-volume residual disease (no more than 5 clinically enlarged retroperitoneal masses, size < 5 cm, no adjacent organ or vascular invasion) between 2006 and 2011 were identified. Clinicodemographic information and pathological outcomes were reported.
Results: Median age of our study population was 32 (interquartile range [IQR]: 28-39). Most patients presented with clinical stage II disease (63%) and were… More >

Avik Som^1,2, Li Xiao³, Rui Zhu⁴, Charles C. Guo³, Lianchun Xiao⁵, Priya Rao³, Eleni Efstathiou¹, Angabin Matin⁴, Shi-Ming Tu¹

Canadian Journal of Urology, Vol.20, No.4, pp. 6860-6867, 2013

Abstract Introduction: A small subset of young men die from seminoma. Studying these high risk, clinically atypical seminomas (CASs)—aggressive tumors with visceral metastases and chemotherapy resistance—may provide clues to the nature of drug resistance and the origin of testicular cancers. We explored the possibility that these seminomas are a unique clinical and biologic entity with intrinsic yolk sac tumor (YST) features.
Materials and methods: We assayed available archived tissue samples (n = 22) for chemotherapy-resistance markers found in YSTs. Specifically, we analyzed tissues and clinical histories from patients with CASs (those who had visceral metastases and recurrent disease),… More >

Ryan W. Dobbs¹, Adeboye O. Osunkoya^1,2, Peter T. Nieh¹, Daniel J. Canter¹

Canadian Journal of Urology, Vol.19, No.5, pp. 6471-6473, 2012

Abstract Testicular cancer is the most common solid malignancy of men aged 15-40 years and metastasizes in a predictable manner via lymphatic spread. Involvement of metastatic testicular cancer to the prostate is an exceedingly rare event which has only been previously described in patients with seminomatous germ cell tumors. In this report, we present a case of a 42-year-old man who presented with metastatic testicular cancer to the prostate 8 years after his original diagnosis of a mixed germ cell left testicular tumor. More >

Jason Rothman¹, Richard E. Greenberg², William I. Jaffe¹

Canadian Journal of Urology, Vol.15, No.3, pp. 4122-4124, 2008

Abstract Extragonadal germ cell tumors are extremely rare and account for only 3%-5% of all germ cell tumors. These tumors are rarely associated with metachronous primary testicular germ cell tumors. We report the fourth case of a primary germ cell tumor occurring after the treatment of a primary CNS germ cell tumor in a 27-year-old male with embryonal cell carcinoma of the testicle 9 years after the treatment of a germ cell tumor of the pineal gland. This represents the fi rst case of a non-seminomatous germ cell tumor of the testicle after a CNS germ More >

Abdulhadi Aldejmah¹, Denis Soulières², Fred Saad²

Canadian Journal of Urology, Vol.14, No.1, pp. 3458-3460, 2007

Abstract Bone metastasis is usually a late manifestation in patients with germ cell tumors and a poor prognosis site. We report a case of 29-year-old man with a nonseminomatous germ cell tumor who presented with a single metastatic site in a vertebrae with spinal compression. He was treated with a left orchiectomy and four cycles of chemotherapy containing bleomycin,etoposide, and cisplatin. He attained complete remission. More >

Mustafa Sofikerim¹, Deniz Demirci¹, Figen Öztürk², Atila Tatlisen¹

Canadian Journal of Urology, Vol.14, No.2, pp. 3510-3513, 2007

Abstract This report describes an exceptionally rare case of a 64- year-old man with seminoma in abdominal cryptorchidism, leading to intestinal obstruction 40 years after curative treatment for seminoma of the other (descended) testis. More >